JMB-HEADER RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2022  1,200
2021  1,540
2020  1,374
2019  1,023
2018  0,932
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 49(2015) N 6 p. 858-866; DOI 10.1134/S0026893315050076 Full Text

A.E. Gareeva1*, K.O. Kinyasheva1, D.Yu. Galaktionova2, E.T. Sabirov3, R.G. Valinourov4, A.V. Chudinov2, A.S. Zasedatelev2, T.V. Nasedkina2, E.K. Khusnutdinova2,5

Polymorphism of brain neurotransmitter system genes: Search for pharmacogenetic markers of haloperidol efficiency in Russians and Tatars

1Institute of Biochemistry and Genetics, Ufa Scientific Center, Russian Academy of Sciences, Ufa, 450054 Russia;
2Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia
3Polyclinic of Ufa Scientific Center, Russian Academy of Sciences, Ufa, 450054 Russia
4Republican Psychiatric clinic no. 1, Ministry of Health of the Republic of Bashkortostan, Ufa, 450069 Russia
5Bashkir State University, Ufa, 450076 Russia

*annagareeva@yandex.ru
Received - 2015-02-17; Accepted - 2015-04-11

cccccAntipsychotics are the primary drugs for treating schizophrenia, a severe psychical disease that affects approximately 1% of the population. The mechanism of antipsychotic action has not yet been completely clarified. A number of studies in the field of pharmacogenetics have confirmed the huge influence of several neurotransmitter systems on the efficiency and development of side effects. In the present work, we studied whether there are associations between nine polymorphic variants of five genes of dopaminergic and serotonergic systems (DRD4, HTR2A, TPH1, SLC18A1, and COMT) in schizophrenia patients (Russians and Tatars) and the efficiency of therapy by haloperidol (a typical antipsychotic) according to the positive and negative syndrome scale (PANSS). Interethnic differences in the specificity of genetic factors of sensitivity to haloperidol therapy have been registered. Pharmacogenetic markers of increased and decreased efficiency of the therapy by this drug were established in patients of Russian ethnicity. No genetic markers of the efficiency of haloperidol therapy in the studied genes have been detected in patients of Tatar ethnicity. These results confirm the significance of changes in nucleotide sequences of all studied dopaminergic and serotonergic system genes in the development of individual sensitivity to haloperidol. We consider our data to be preliminary (before their confirmation on larger patient samples).

dopamine receptor (DRD4) gene, catechol-O-methyltransferase (COMT) gene, serotonin receptor (HTR2A) gene, tryptophan hydroxylase 1 (TPH1) gene, solute transporter 18 family genes, member 1 (SLC18A1), schizophrenia, pharmacogenetics, antipsychotics



JMB-FOOTER RAS-JOURNALS